Descrizione del progetto
Progressi nella somministrazione controllata dei farmaci orali
Gli acidi e gli enzimi presenti nell’apparato digerente dello stomaco e l’incapacità dei farmaci di attraversare la barriera della membrana intestinale possono ostacolare una somministrazione efficace dei farmaci orali, in particolare di quelli a base di proteine o peptidi. L’obiettivo del progetto FREJA, finanziato dall’UE, è superare queste difficoltà attraverso la progettazione e lo sviluppo di metodi innovativi che proteggano i principi attivi fino al momento in cui raggiungono la parte interessata dell’intestino del paziente. Pertanto, le attività includeranno lo sviluppo di dispositivi autoconfigurabili e che abilitano la prossimità, i quali potranno incorporarsi nel tessuto intestinale per somministrare i farmaci (tale soluzione risulterà utile principalmente per l’insulina utilizzata dai pazienti diabetici). Il progetto darà vita a una nuova tecnologia trasferibile, che consentirà di somministrare vaccini sotto forma di pillola.
Obiettivo
Oral delivery of protein/peptide drugs is extremely challenging and the majority of research in the field is based on exploring new formulations, for instance using permeation enhancers. In recent years, some research has been done on ingestible devices for internal injections. Here I propose an entirely new approach based on what we have named ‘Self-configurable, Proximity Enabling Devices’ (SPEDs). The idea is that these devices (the simplest ones will be rolled-up foils) will unfold in the gut, embed in the mucus layer and align to the intestinal wall. It is essential that the SPED has close proximity to the intestinal wall and is retained for a while in order to ensure efficient drug delivery. The proximity will additionally allow us to study and explore the influence of nanotextures (embedded in the SPED) on the interaction with the intestinal wall as well as micromotor-based delivery. The SPEDs will be developed and characterized with the following specific objectives: (i) understanding the SPED properties needed to penetrate mucus, (ii) investigating the mechanisms for enhanced retention time, (iii) exploring the SPED as a carrier for self-propelling cargo, (iv) unraveling the overall behaviour of SPED and (v) demonstrating anti-diabetic drug formulation delivery with at least 5 % systemic uptake and show feasibility of a wider range of applications (delivering/seeding e.g. peptide and proteins/vaccines/probiotics). The work will include simulations of soft materials, device design, micro/nano fabrication, development and use of techniques for mechanical characterisation of device/tissue interaction, bio imaging and in vitro and in vivo studies. The major novelty lies in the SPED concept, providing tissue alignment/contact and unidirectional drug release. Further, the SPEDs provide a unique platform for studies on micromotors as well as nanotextures interaction with the epithelium.
Parole chiave
Programma(i)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Argomento(i)
Meccanismo di finanziamento
HORIZON-ERC - HORIZON ERC GrantsIstituzione ospitante
2800 Kongens Lyngby
Danimarca